Entity family
Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.
This disease is selected. Its supporting articles are shown below.
…ollowing CAR-T therapy in patients with leukemia, lymphoma, and myeloma.Methods MEDLINE, Embase, Web of Science, and Cochrane CENTRAL d…
…cal success in hematologic malignancies, but remains limited in solid tumors due to immune checkpoint-mediated suppression and intrinsic sig…
…Background In the antiretroviral therapy (ART) era, Pneumocystis jirovecii pneumonia (PJP) has become uncommon among people living with HIV (PWH) re…
…particularly in hematologic malignancies, but their efficacy in solid tumors remains limited. Key barriers include tumor antigen heterogenei…
…T-cell(CAR T-cell) therapies have demonstrated effectiveness in hematologic malignancies in pivotal trials. However, real-world evidence remains limited…
…-T cell therapy targeting CD19 has transformed the treatment of hematologic malignancies. The costimulatory domain (CSD) of CAR constructs plays a cruci…
…omal barriers and enhance the efficacy of CAR-T cell therapy in solid tumors.…
…romising clinical progress in both hematologic malignancies and solid tumors; however, their therapeutic efficacy is still limited by multip…
… (CAR-T) has shown high efficacy and safety in treating various hematologic malignancies. However, many hematologic disorders, such as BCR::ABL1-negativ…
…ell therapy has transformed the treatment landscape for certain hematologic malignancies, therapeutic resistance and disease relapse highlight the criti…
…e of surface proteins amenable to CAR-T cell-based therapies in solid tumors.…
…me limitations of conventional bispecific TCEs, particularly in AML patients with high disease burden, thus supporting clinical exp…